Intoxications with the monoamine oxidase inhibitor tranylcypromine: An analysis of fatal and non-fatal events

European Neuropsychopharmacology

Volumn 23, Issue 11, 2013, Pages 1364-1372

  Gahr, Maximilian ^a   Schönfeldt Lecuona, Carlos ^a   Kölle, Markus A ^a   Freudenmann, Roland W ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Adverse events; Antidepressants; Major depression; Psychopharmacology; Suicide; Toxicology

Indexed keywords

TRANYLCYPROMINE;

AGE; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; COGNITIVE DEFECT; CONSCIOUSNESS DISORDER; DELIRIUM; DISEASE SEVERITY; DRUG EFFICACY; DRUG INTOXICATION; DRUG OVERDOSE; FATALITY; HUMAN; HYPERTHERMIA; KIDNEY FAILURE; MAJOR DEPRESSION; MUSCLE RIGIDITY; PRIORITY JOURNAL; RESPIRATORY DISTRESS; REVIEW; RISK FACTOR; SEROTONIN SYNDROME; SUICIDAL BEHAVIOR; SURVIVAL; SYMPTOMATOLOGY; SYSTEMATIC REVIEW;

ADVERSE EVENTS; ANTIDEPRESSANTS; MAJOR DEPRESSION; PSYCHOPHARMACOLOGY; SUICIDE; TOXICOLOGY;

DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MONOAMINE OXIDASE INHIBITORS; TRANYLCYPROMINE;

EID: 84886796319     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2013.05.009     Document Type: Review

References (71)

1. Abdi S., Fishman S. Acute exacerbation of depression after discontinuation of monoamine oxidase inhibitor prior to cardiac surgery. Anesth. Analg. 1996, 83:656-657.
2. Absher J., Black D. Tranylcypromine withdrawal delirium. J. Clin. Psychopharmacol. 1988, 8:379-380.
3. Adli M., Berghöfe R.A., Linden M., Helmchen H., Müller-Oerlinghausen B., Mackert A., Stamm T., Bauer M. Effectiveness and feasibility of a standardized stepwise drug treatment regimen algorithm for inpatients with depressive disorders: results of a 2-year observational algorithm study. J. Clin. Psychiatry 2002, 63:782-790.
4. Adli M., Philhatsch M., Bauer M., Köberle U., Rickern R., Janssen G., Ulrich S., Bschor T. Safety of high-intensity treatment with the irreversible monoamine oxidase inhibitor tranylcypromine in patients with treatment-resistent depression. Pharmacopsychiatry 2008, 41:252-257.
5. Amsterdam J., Shults J. MAOI efficacy and safety in advanced stage treatment-resistant depression-a retrospective study. J. Affect. Disord. 2005, 89:183-188.
6. Asatoor A., Levi A., Milne M. Tranylcypromine and cheese. Lancet 1963, 54:733-734.
7. Bacon G. Successful suicide with tranylcypromine sulfate. Am. J. Psychiatry 1962, 119:585.
8. Baker G., Coutts R., McKenna K., Sherry-McKenna R. Insights into the mechanisms of action of the MAO inhibitors phenelzine and tranylcypromine: a review. J. Psychiatr. Neurosci. 1992, 17:206-214.
9. Baker G., Martin I., Mitchel P. The effects of some indolalkylamines on the uptake and release of 5-hydroxytryptamine in rat striatum. Br. J. Pharmacol. 1977, 61:151P-152P.
10. Baumbacher G., Hansen M. Abuse of monoamine oxidase inhibitors. Am. J. Drug Alcohol Abuse 1992, 18:399-406.
11. Beavan T. The cheese reaction. Lancet 1964, 1:540.
12. Bell D., Scaff J. Fatal reaction to tranylcypromine (Parnate). Hawaii Med. J. 1963, 22:440-441.
13. Bethune N., Burrell R., Culpan R. Headache associated with monoamine oxidase inhibitors. Lancet 1963, 2:1233-1234.
14. Billett E. Monoamine oxidase (MAO) in human peripheral tissues. Neurotoxicology 2004, 25:139-148.
15. Birkenhäger T., van den Broek W., Mulder P., Bruijn J., Moleman P. Efficacy and tolerability of tranylcypromine versus phenelzine: a double-blind study in antidepressant-refractory depressed inpatients. J. Clin. Psychiatry 2004, 65:1505-1510.
16. Blackwell B. Hypertensive crisis due to monoamine-oxidase inhibitors. Lancet 1963, 2:849-850.
17. Blazer D., van Nieuwenhuizen A. Evidence for the diagnostic criteria of delirium: an update. Curr. Opin. Psychiatry 2012, 25:239-243.
18. Boniface P. Two cases of fatal intoxication due to tranylcypromine overdose. J. Anal. Toxicol. 1991, 15:38-40.
19. Boulton M., Juorio A. Brain trace amines. Handbook of Neurochemistry 1982, Plenum Press, New York, pp. 189-222. A. Lajtha (Ed.).
20. Boyer E., Shannon M. The serotonin syndrome. N. Engl. J. Med. 2005, 352:1112-1120.
21. Briggs N., Jefferson J., Koenecke F. Tranylcypromine addiction: a case report and review. J. Clin. Psychiatry 1990, 51:426-429.
22. Brubacher J., Hoffmann R., Lurin M. Serotonin syndrome from venlafaxine-tranylcypromine interaction. Vet. Hum. Toxicol. 1996, 38:358-361.
23. Chatterjee A., Tosyali M. Thrombocytopenia and delirium associated with tranylcypromine overdose. J. Clin. Psychopharmacol. 1995, 15:143-144.
24. Cuthill J., Griffiths A., Powell D. Death associated with tranylcypromine and cheese. Lancet 1964, 1:1076-1077.
25. Davids E., Röschke J., Klawe C., Gründer G., Schmoldt A. Tranylcypromine abuse associated with delirium and thrombocytopenia. J. Clin. Psychopharmacol. 2000, 20:270-271.
26. Degner D., Porzig J., Ruther E., von Lewinski D. Serotonin syndrome with severe hyperthermia after ingestion of tranylcypromine combined with serotinin reuptake inhibitors and tyramine-rich food in a case of suicide. Pharmacopsychiatry 2010, 43:284-285.
27. Dilsaver S. Monoamine oxidase inhibitor withdrawal phenomena: symptoms and pathophysiology. Acta Psychiatr. Scand. 1988, 78:1-7.
28. Dilsaver S. Heterocyclic antidepressant, monoamine oxidase inhibitor and neuroleptic withdrawal phenomena. Prog. Neurpsychopharmacol. Biol. Psychiatry 1990, 14:137-161.
29. Eyer F., Jetzinger E., Pfab R., Zilker T. Withdrawal from high-dose tranylcypromine. Clin. Toxicol. (Philadelphia) 2008, 46:261-263.
30. Fischbach R. Suicide attempt using Jatrosome. Wien. Med. Wochenschr. 1968, 118:654-656.
31. Frieling H., Bleich S. Tranylcypromine: new perspectives of an "old" drug. Eur. Arch. Psychiatry Clin. Neurosci. 2006, 256:268-273.
32. Graham W. Hypertension caused by tranylcypromine and cheese. J. Am. Med. Assoc. 1964, 187:782.
33. Griffiths G. Overdose of Parstelin (tranylcypromine). Med. Sci. Law 1973, 13:93-94.
34. Iwersen S., Schmoldt A. One fatal and one nonfatal intoxication with tranycypromine. Absence of amphetamines as metabolites. J. Anal. Toxicol. 1996, 20:301-304.
35. Jacobziner H., Raybin H. Accidental chemical poisonings. Hydralzine hydrocholoride, mercury, tranylcpromine, and permanganate intoxications. N. Y. State J. Med. 1963, 63:1210-1213.
36. Jones R. Tryptamine: a neuromodulator or neurotransmitter in mammalian brain?. Prog. Neurobiol. 1982, 19:117-139.
37. Jones R. Trace biogenic amines: a possible functional role in the CNS. Trends Pharmacol. Sci. 1983, 4:426-429.
38. Kalgutkar A., Dalvie D., Castagnoli N., Taylor T. Interactions of nitrogen-containing xenobiotics with monoamine oxidase (MAO) isoenzymes A and B: SAR studies on MAO substrates and inhibitors. Chem. Res. Toxicol. 2001, 14:1139-1162.
39. Le Gassicke J. Trancylcypromine. Lancet 1963, 281:269-270.
40. Le Gassicke J., Ashcroft G., Eccleston D., Evans J., Oswald I., Ritson E. The clinical state, sleep and amine metabolism of a tranylcypromine ('Parnate') addict. Br. J. Psychiatry 1965, 111:357-364.
41. Leon A., Solomon D., Li C., Fiedorowicz J., Coryell W., Endicott J., Keller M. Antidepressants and risks of suicide and suicide attempts: a 27-year observational study. J. Clin. Psychiatry 2011, 72:580-586.
42. Levkovitz Y., Tedeschini E., Papakostas G. Efficacy of antidepressants for dysthymia: a meta-analysis of placebo-controlled randomized trials. J. Clin. Psychiatry 2011, 72:509-514.
43. Maccaig J., Edmondson J. Overdose of Parstelin. Br. Med. J. 1965, 1:923.
44. Mackell M., Case M., Poklis A. Fatal intoxication due to tranylcypromine. Med. Sci. Law 1979, 19:66-69.
45. Mandour R. Antidepressants medications and the relative risk of suicide attempt. Toxicol. Int. 2012, 19:42-46.
46. Marra J., Minter D., Hobbins T. Suicide by the ingestion of tranylcypromine. J. Am. Med. Assoc. 1965, 192:1104-1105.
47. Matter B., Donat P., Brill M., Ginn H.J. Tranylcypromine sulfate poisoning: successful treatment by hemodialysis. Arch. Intern. Med. 1965, 116:18-20.
48. Mawdsley J. "Parstelin". A case of fatal overdose. Med. J. Aust. 1968, 2:292.
49. McGrath P., Stewart J., Fava M., Trivedi M., Wisniewski S., Nierenberg A., Thase M., Davis L., Biggs M., Shores-Wilson K., Luther J., Niederehe G., Warden D., Rush A. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STARD report. Am. J. Psychiatry 2006, 163:1531-1541. quiz 1666.
50. Midwinter R. Accidental overdosage of Parsteline. Br. Med. J. 1962, 2:1755-1756.
51. Nardi A., Lopes F., Valenca A., Freire R., Nascimento I., Veras A., Mezzasalma M., de-Melo-Neto V., Soares-Filho G., King A., Grivet L., Rassi A., Versiani M. Double-blind comparison of 30 and 60mg tranylcypromine daily in patients with panic disorder comorbid with social anxiety disorder. Psychiatry Res. 2012, 175:260-265.
52. Pae C., Tharwani H., Marks D., Masand P., Patkar A. Atypical depression: a comprehensive review. CNS Drugs 2009, 23:1023-1037.
53. Parker G., Wilhelm K., Mitchell P. Assessing the comparative effectiveness of antidepressant therapies: a prospective clinical practice study. J. Clin. Psychiatry 2001, 62:17-25.
54. Paterson I., Boulton M. Beta-phenylethylamine enhances single cortical neurone responses to noradrenaline in the rat. Brain Res. Bull. 1988, 20:173-177.
55. Paterson I., Iurio A., Boulton M. 2-Phenylethylamine: a modulator of catecholamine transmission in the mammalian central nervous system?. J. Neurochem. 1990, 55:1827-1837.
56. Pennings E., Verkes R., de Koning J., Bommelé J., Jansen G., Vermeij P. Tranylcypromine intoxication with malignant hyperthermia, delirium, and thrombocytopenia. J. Clin. Psychopharmacol. 1997, 17:430-432.
57. Philips S., Boulton M. The effects of monoamine oxidase inhibitors on some arylalkylamines in rat striatum. J. Neurochem. 1979, 33:159-167.
58. Quante A., Zeugmann S. Tranylcypromine and bupropion combination therapy in treatment-resistant major depression: a report of 2 cases. J. Clin. Psychopharmacol. 2012, 32:572-574.
59. Raiteri M., Del Carmine R., Bertollini A., Levi G. Effect of sympathomimetic amines on the synaptosomal transport of noradrenaline, dopamine and 5-hydroxytryptamine. Eur. J. Pharmacol. 1977, 41:133-142.
60. Robertson J. Recovery after massive MAOI overdose complicated by malignant hyperpyrexia, treated with chlorpromazine. Postgrad. Med. J. 1972, 48:64-65.
61. Shih J., Chen K. Regulation of MAO-A and MAO-B gene expression. Curr. Med. Chem. 2004, 11:1995-2005.
62. Smith D. Tranylcypromine stereoisomers, monoaminergic neurotransmission and behavior. A minireview. Pharmakopsychiatr. Neuropsychopharmakol. 1980, 13:130-136.
63. Stewart J., Thase M. Treating DSM-IV depression with atypical features. J. Clin. Psychiatry 2007, 68:e10.
64. Szelényi A., Albrecht J. Tranylcypromine abuse associated with an isolated thrombocytopenia. Pharmacopsychiatry 1998, 31:238-240.
65. Thorp M., Toombs D., Harmon B. Monoamine oxidase inhibitor overdose. West. J. Med. 1997, 166:275-277.
66. Tuomisto J., Smith D. Effects of tranylcypromine enantiomers on monoamine uptake and release and imipramine binding. J. Neural Transm. 1986, 65:135-145.
67. Tuomisto J., Tuomisto L., Smissman E. Conformation study of the inhibition of monoamine uptake in rat brain synaptosomes. Ann. Med. Exp. Biol. Fenn. 1973, 51:51-58.
68. van Haelst I., Van Klei W., Doodeman H., Kalkman C., Egberts T. Antidepressive treatment with monoamine oxidase inhibitors and the occurrence of intraoperative hemodynamic events: a retrospective observational cohort study. J. Clin. Psychiatry 2012, 1103-1109.
69. Vieta E., Colom F. Therapeutic options in treatment-resistant depression. Ann. Med. Exp. Biol. Fenn. 2011, 43:512-530.
70. Vieta E., Locklear J., Günther O., Ekman M., Miltenburger C., Chatterton M., Aström M., Paulsson B. Treatment options for bipolar depression: a systematic review of randomized, controlled trials. J. Clin. Psychopharmacol. 2010, 30:579-590.
71. Youdim M., Aronson J., Blau K., Green A., Grahame-Smith D. Tranylcypromine ('Parnate') overdose: measurement of tranylcypromine concentrations and MAO inhibitory activity and identification of amphetamines in plasma. Psychol. Med. 1979, 9:377-382.